Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 39 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Συντάκτης is Terpos, Evangelos  [Clear All Filters]
Journal Article
Polyzos, S. A., Anastasilakis A. D., & Terpos E. (2009).  Paget's disease of bone: emphasis on treatment with zoledronic acid.. Expert Rev Endocrinol Metab. 4(5), 423-434.
Polyzos, S. A., Makras P., Anastasilakis A. D., Mintziori G., Kita M., Papatheodorou A., et al. (2017).  Periostin and sclerostin levels in juvenile Paget's disease.. Clin Cases Miner Bone Metab. 14(2), 269-271.
Gavriatopoulou, M., Kastritis E., Kyrtsonis M-C., Vassilakopoulos T. P., Roussou M., Fotiou D., et al. (2017).  Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia.. Leuk Lymphoma. 58(6), 1506-1508.
Polyzos, S. A., Anastasilakis A. D., Litsas I., Efstathiadou Z., Kita M., Arsos G., et al. (2010).  Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.. J Bone Miner Metab. 28(6), 706-12.
Anastasilakis, A. D., Toulis K. A., Polyzos S. A., & Terpos E. (2009).  RANKL inhibition for the management of patients with benign metabolic bone disorders.. Expert Opin Investig Drugs. 18(8), 1085-102.
Katodritou, E., Kyrtsonis M-C., Delimpasi S., Kyriakou D., Symeonidis A., Spanoudakis E., et al. (2018).  Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.. Ann Hematol. 97(9), 1671-1682.
Katodritou, E., Terpos E., Delimpasi S., Kotsopoulou M., Michalis E., Vadikolia C., et al. (2018).  Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.. Blood Cancer J. 8(3), 31.
Kastritis, E., Gavriatopoulou M., Roussou M., Migkou M., Fotiou D., Ziogas D. C., et al. (2017).  Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy.. Am J Hematol. 92(7), 632-639.
Polyzos, S. A., Anastasilakis A. D., Efstathiadou Z., Litsas I., Kita M., Panagiotou A., et al. (2010).  Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid.. J Bone Miner Metab. 28(3), 314-9.
Makras, P., Polyzos S. A., Anastasilakis A. D., Terpos E., Papatheodorou A., & Kaltsas G. A. (2012).  Is serum IL-17A a useful systemic biomarker in patients with Langerhans cell histiocytosis?. Mol Ther. 20(1), 6-7.
Makras, P., Polyzos S. A., Anastasilakis A. D., Terpos E., Kanakis G., Schini M., et al. (2012).  Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis.. J Clin Endocrinol Metab. 97(4), E618-21.
Makarona, K., Caputo V. S., Costa J. R., Liu B., O'Connor D., Iskander D., et al. (2014).  Transcriptional and epigenetic basis for restoration of G6PD enzymatic activity in human G6PD-deficient cells.. Blood. 124(1), 134-41.
Polyzos, S. A., Anastasilakis A. D., & Terpos E. (2009).  Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid.. Support Care Cancer. 17(10), 1329-30.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., & Terpos E. (2023).  Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease: Potential therapeutic implications.. Hepatobiliary Pancreat Dis Int.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές